Abstract
Introduction
Prostate cancer (CaP) is the second leading cause of cancer-related deaths among men in the United States (1) . The molecular determinants in the development and progression of this disease are poorly understood. In recent years, increasing attention has been directed to finding genes that play a causal role in the process of tumorigenesis, such as tumor suppressor genes (TSGs) and oncogenes. Chromosomal loci, which are associated with sporadic as well as inherited CaPs, are being intensely analyzed for putative TSGs or proto-oncogenes. High frequency of allelic losses on 8p2l-22, 10q23-25, 7q31, and 16q24 loci have been shown in CaP. There has been extensive work from several laboratories on the characterization of chromosome 8p21-22 locus, but the identity of tumor suppressor gene has remained elusive (2-7). NKX3.1 on the 8p21 locus has been suggested as a candidate TSG. However, no tumor-associated mutations have been reported (6) . PTEN/MMACI on chromosome 10q25 has been discovered as a TSG frequently altered in advanced CaP (8, 9) . ST7 on chromosome 7q has been identified to be mutated in prostate and other cancers (10) . Mutations of the KLF6 gene on chromosome 10p have also been recently reported in sporadic CaPs (11) . On the other hand, gains of chromosome 8q24 harboring c-myc and prostate stem cell antigen (PSCA) genes have also been shown in CaP (12) . Studies utilizing comparative genomic hybridization (CGH) have shown frequent losses of novel chromosomal loci including 2q, 5q, and 6q and gains of 11p, l2q, 3q, 4q, and 2p in CaP (13) . Our own study shows the high rate of LOH on 6q16 using laser capture microdissection (LCM)-derived CaP specimens (14) . Chromosome regions 1q, 13q, 17p, 20q, and Xq have been linked to familial CaP (15, 16) . Recent reports have described germline mutations of the ELAC2 and RNASEL1 in a small subset of CaP-prone families (17) (18) (19) . Thus, identification and analysis of candidate genes in CaP-associated chromosomal deletion region have promise in defining CaP-specific TSGs and/or oncogenes.
Deletions and allelic imbalance (AI) on human chromosomal region 16q21-24 have been detected by various genetic approaches in human CaP, as well as other cancers, including breast cancer, Wilm's tumors, hepatocellular carcinoma, and acute myeloid leukemia (20) (21) (22) (23) (24) (25) (26) . These observations suggest that this region may harbor multiple tumor suppressor loci, which might be implicated in the development of CaP and other malignancies (27) . In the search for tumor suppressor genes that are the targets of loss of heterozygosity on 16q, the E-cadherin gene, CDH1, was unveiled by the identification of mutations and/or diminished expression in CaP and other malignancies (28) (29) (30) . Investigations are still in progress to find the target genes from this region in prostate tumors. We report here the cloning and the characterization of a novel gene named DERPC that locates on 16q22.1, 260 kbp apart from the CDH1 locus. The expression of DERPC was found to be significantly decreased in renal tumors, as well as in prostate tumors. DRPEC encodes a nuclear protein with cell growth inhibitory characteristics. We suggest that decreased expression of DRPEC may play a role in the process of tumorigenesis in renal and prostate tumors.
Materials and Methods

Cell Culture
Prostate tumor cell lines DU145, LNCaP, and PC3 and kidney embryonic cells 293 cells were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and were maintained in growth medium recommended by the supplier.
Full-Length DERPC cDNA Sequence
IMAGE clones of EST were purchased from ATCC and sequenced using primers from 5Ј and 3Ј ends of the vector followed by internal primers designed from the initial sequence data. Full-length cDNA was obtained by RT-PCR. DNA sequencing was performed using the AmpliCycle sequencing kit from Applied Biosystems (Foster City, CA, USA) on 3100 DNA Genetic Analyzer.
Northern and Dot Blot Analysis
Northern blots containing multiple human tissue mRNA and multi-tumor array were purchased from Clontech. The probe was labeled with 32 P-dCTP by random priming (Stratagene) following the manufacturer's directions. Hybridization was carried out at 68 ЊC for 12-14 hr in ExpressHyb Solution (Clontech) containing 1 ϫ 10 6 /ml 32 P-labled probe followed by stringent washing in 0.1% SDS, 2XSSC at room temperature, and 0.1% SDS, 0.1XSSC at 68 ЊC. The membranes were exposed to a Kodak XR film for autoradiography.
Quantitative RT-PCR
Matched normal and tumor samples were obtained by LCM of frozen sections derived from radical prostatectomy specimens. Total RNA was extracted from cells by RNAzol method (Gibco BRL). Total RNA was reverse transcribed and subjected to quantitative PCR. The quantitative PCR was performed using SYBR green PCR kit (Applied Biosystems) on PE-7700 Sequence Detection System. Ct value obtained from gene specific primers was used to calculate the expression difference between normal and tumor samples after calibration with the Ct value from housekeeping gene GAPDH.
Bioinformatics
The cDNA sequence was searched for homology and similarity against GenBank using BLAST programs, including BLASTN, BLASTX, and BLASTP (available from URL: http://www.ncbi.nlm.nih.gov). Predicted protein sequence was analyzed by webbased sofware: TMPred (available from URL: http:// www.ch.embnet.org/software/TMPRED_form.html), ProfileScan (available from URL: http://www.isrec. isb-sib.ch/software/PFSCAN_form.html), ScanProsite (available from URL: http://expasy.cbr.nrc.ca/tools/ scnpsit1.html), and Interpro (available from URL: http://www.ebi.ac.uk/interpro/). We performed alignment of protein sequences using ClustalW Multiple Sequence Alignment (@BCM) (available from URL: http://dot.imgen.bcm.tmc.edu:9331/multi-align/Options/clustalw.html).
Construction of Expression Plasmid
Wild-type DERPC cDNA was obtained by RT-PCR amplification of the entire open reading frame (ORF) of DERPC from human prostate Marathon-Ready cDNA (Clontech) using forward primer (TGGT-GACAGCACTCATCAAAGACAAG) and reverse primer (GGCTGGAGATCCTTTCTCTCAAGG), followed by cloning into PCR-blunt II TOPO vector (Invitrogen). DERPC was excised from PCR-blunt II by EcoR I digestion and inserted into mammalian (5 g) was transfected into tumor cells using TransFast reagent (Promega, Madison, WI, USA) according to the protocols provided by the manufacturer. The cells were then cultured in medium containing 400-500 g/ml of geneticin (G-418) for 2-4 weeks. Cell colonies were stained with crystal violet.
Results
Isolation and Characterization of DERPC
An EST sequence of DERPC, localizing to chromosome 16q22.1, was initially selected from Serials Analysis of Gene Expression (SAGE) library of genes expressed in LNCaP cells (31) . The notable chromosomal localization of DERPC on 16q22.1, which is frequently altered in various types of human tumors, caused us to further investigate DERPC. A 2.9-kbp cDNA sequence of DERPC was assembled by sequence analysis of EST IMAGE clones and PCR-derived DNA fragment from normal prostate cDNA (Fig. 1B) . Complete cDNA sequence revealed a single open reading frame (ORF) of 1575 nucleotides encoding a protein of 524 amino acids with an approximate molecular mass of 51 kDa. Then DERPC cDNA sequence was compared to GenBank using BLASTN, which identified the human chromosome 16 clone RP11-123C5 (GenBank accession number AC009027.10). We constructed a physical map of this region based on the Ensembl Human ContigView (available from URL: http://www. ensembl.org/Homo_sapiens) (Fig. 1A) . The genomic structure of DERPC was determined by aligning the cDNA sequence against the genomic sequence of chromosome 16 clone RP11-123C5. DERPC is composed of four exons that span 14.5 kbp of genomic DNA. However, the entire ORF was localized in exon 4 (Fig. 1A) .
The DERPC is a highly basic protein with PI of 12.5. It contains abundant proline (20%) and glycine (18%) residues. Structural analysis of the amino acid sequence using the TMpred membranespanning-prediction program (TMpred-Prediction of Transmembrane Regions and Orientation) revealed absence of significant transmembrane domain in the DERPC encoded protein, suggesting that DERPC encodes a nonmembrane protein. Comparison of the amino acid sequence with known protein motifs and patterns at ProfileScan identified a prolineglycine rich domain (AA4-467). Furthermore, the predicted DERPC peptide contained 11 repeats of the sequence PXXP (where P represents proline and X any amino acid), which is known to bind to the SH3 domain (Fig. 1B) . We therefore predict that DERPC encodes a proline-glycine rich protein potentially interacting with SH3 containing proteins implicated in signal transduction.
The predicted DERPC peptide shared an 86% sequence homology with a human hypothetical protein (GenBank accession: xm_093070) and an 82% mouse homolog (accession: BC023107) (Fig. 2) . The expression vector pcDNA3.1(ϩ) (Invitrogen) to generate pcDNA-DERPC sense and antisense constructs.
The construct encoding green fluorescent protein (GFP)-DERPC was generated by in-frame insertion of DERPC from PCR-blunt II TOPO into pEGFP-C1 at EcoR I site. A spacer peptide encoded by the multiple cloning sites of the GFP vector YKSGLRSRAQA-SNSPFGDSTHQRQDPFQNPPQAHYHQRPQES was included between GFP and DERPC. To generate the construct encoding DERPC-GFP, we introduced a 7-glycine linker in-frame followed by a PinA I site into 3Ј end of DERPC to replace its stop codon by PCR. PCR product of DERPC was then cut by KpnI and PinAI and inserted in-frame into the same sites in pEGFP-N1. An amino acid sequence GGGGGGGQPVAT containing the glycine linker and the codons derived from the multiple cloning sites of the GFP vector was created between DERPC and GFP. All constructs were verified by DNA sequencing.
Transfection
Cells were seeded at approximately 40-60% confluence in 2-well Lab-Tek chambered slides 18-24 hr before transfection. Transient transfection was carried out using FuGene6 reagent (Boehringer Mannheim) following the guidelines supplied by the manufacturer. Briefly, cells were incubated with DNA/FuGene6 mixture in OPTI Medium (Invitrogen) for 2-5 hr followed by culturing in medium containing an appropriate concentration of FBS. Cells were fixed 48-72 hr after transfection with 3% paraformaldehyde for 30 min and stained with DAPI.
Confocal Microscopy
Confocal images were obtained with an LSM410 confocal microscope (Carl Zeiss Inc., Thornwood, USA, NY) equipped with an Omnichrome kryptonargon laser (Melles Griot, Carlsbad, CA, USA) with excitation wavelengths of 488 nm for EGFP and an argon ion laser (Coherent, Santa Clara, CA) with excitation wavelength of 351 nm for DAPI staining.
Immunoblotting
Cells were lysed in 1ϫ SDS lysis buffer and boiled for 10 min. The extract was centrifuged at 10,000 g for 10 min and the supernatant was aliquoted and stored at Ϫ70 ЊC. Total protein (100 g) from each sample was separated on 10% SDS-PAGE gel electrophoresis. The proteins were transferred to nitrocellulose membrane (Novex) and Western blot analysis was performed using an ECL blot kit (Amersham) according to the manufacturer's instruction. Mouse monoclonal antibody (mAb) against GFP (Boehringer Mannheim) was used at a 1:1000 dilution to detect the tagged DERPC.
Colony Formation Assay
Cells (2 ϫ 10 5 ) were seeded in a 60-mm dish 1 day before transfection. The expression plasmid DNA human hypothetical protein contained additional 47 amino acids at the N-terminus derived from a predicted exon. The human homologous gene is localized to chromosome X and encoded 560 amino acids. Because the human hypothetical protein is predicted by automated computational analysis using the gene prediction method, GenomeScan computer program, its true identity remains to be verified. Nevertheless, it is possible that DERPC and the hypothetical protein belong to the same family of proteins. The mouse homolog of DERPC is derived from a cDNA library. It is likely that this gene represents the mouse homolog of DERPC. To define the location of mouse homolog DERPC on mouse genome, we searched mouse genome database using Genomic Blast, which identified two mouse DNA contigs (NW_000349.1 on mouse chromosome 8 and NW_000102.1 on chromosome 15). Comparison of the known gene loci surrounded the mouse DERPC to the human revealed that the nearest mouse Cdh1 locus on chromosome 8 is similar to the corresponding region of human DERPC. The presence of the Cdh1 locus confirms and extends to the region of synteny between human chromosome 16q22.1 and the mouse chromosome 8.
Decreased Expression of DERPC in Renal and Prostate Tumors
Northern blot analysis of multiple human tissue blots showed a 3.0-kb DERPC transcript, which was ubiquitously expressed, with abundant expression in kidney, skeletal muscle, testis, liver, ovary, and heart, and moderate expression in prostate (Fig. 3A) .
To investigate the correlation of DERPC expression with tumors, we probed DERPC cDNA to multitumor array blot. We found a significantly decreased DERPC mRNA in 67% (10/15) of renal tumors compared to matched normal tissues (Fig. 3B) .
DERPC expression was further analyzed in LCMderived CaP specimens by quantitative RT-PCR. DERPC expression was found to be decreased more than 4-fold in 32% (12/38) of prostate tumors as compared to their normal counterparts (Table 1 ). These studies suggest that decreased expression of DERPC might play a role in renal and prostate tumorigenesis.
DERPC Resides in the Nucleus and Alters Morphology of LNCaP Cells
To analyze DERPC cellular location, we generated two constructs by fusing GFP at the N-and C-termini of DERPC, respectively. Expression of the fusion proteins was monitored by both Western blot analysis and confocal microscopy in transiently transfected CaP cell lines, PC3 and LNCaP. To verify whether the fusion proteins were expressed properly, fusion proteins were analyzed with the anti-GFP antibody on Western blot. PC3 cells were transfected with the GFP-tagged DERPC constructs and lysed 48 hr after transfection. An 80-or 83-kDa band was detected in the DERPC-GFP or GFP-DERPC transfected cells with the anti-GFP antibody, which was the expected molecular mass for the chimeric proteins. No significant degraded products were detected in cells expressing chimeric proteins. Parental vectors pEGFP-N1 and pEGFP-C1 expressed 27 and 30 kDa of GFP, respectively (Fig. 4A) . (Fig. 4G) . However, the TUNNEL assay did not reveal apoptosis (data not shown).
Expression of DERPC Inhibits Cell Growth of PC3 Cells
To determine the possibility that DERPC expression may inhibit tumor cell growth, we conducted a colony formation assay. The pcDNA-DERPC sense, pcDNA-DERPC antisense constructs, and empty Confocal microscopy showed that both GFPtagged DERPC chimeric proteins are diffusely spread across the whole nucleus but excluded from the nucleolus (nucleoplasmic) (Figs. 4B and 4D ) counterstained with DAPI (Figs. 4C and 4E ) in PC3 cells transfected with either GFP-DERPC or DERPC-GFP constructs. Interestingly, a prompt change of nuclear morphology was observed in LNCaP cells transfected with GFP-DERPC 72 hr after transfection (Fig. 4F) . The nuclei were enlarged pcDNA3.1(ϩ) vector carrying the neoresistant gene were transfected into PC3 cells, which were then maintained in medium containing G418. The drugresistant colonies were counted 2-4 weeks after transfection. A representative experiment is shown in Figure 5 , which demonstrated that DERPC significantly suppressed the growth of PC3 cells. Results from two separate experiments showed that the colony numbers were reduced by 40-50% compared to the vector and DERPC antisense controls. These data suggest that expression of DERPC inhibited prostate tumor cell growth.
Discussion
Despite the recent advance in the search for tumor suppressor genes in CaP, the target genes in the well-defined chromosome deletion regions remain to be identified. We used an approach of selectively analyzing candidate genes in the frequent chromosomal deletion region such as 16q to search for potential tumor suppressor genes in CaP. A candidate tumor suppressor gene that we have named DERPC located on chromosome 16q22.1 was identified and characterized. Our study demonstrated that DERPC expression was decreased in prostate tumors, as well as in renal tumors. Overexpression of DERPC decreased the number of drug-resistant colonies of prostate tumor cell line, PC3 cells, by stable transfection in a colony inhibition assay. A prominent change of nucleus was found when GFP-DERPC fusion protein was transiently expressed in LNCaP cells. This evidence suggests that DERPC might have a potential tumor-suppressing function.
The presence of a gene mutation is still the most convincing evidence that a gene is a tumor suppressor gene. However, inactivation of a tumor suppressor gene occurs with multiple mechanism including mutation of allele and LOH of remaining allele or silencing of expressing by methylation of promoter region of a gene. Epigenetic silencing of a tumor suppressor gene is often induced by hypermethylation of the promoter region. Hypoinsufficiency occurs when only one allele of the tumor suppressor gene is inactivated. We approached to analyze gene expression as well as gene mutation for the initial screening of candidate tumor suppressor genes in frequently altered, tumor-associated chromosomal regions. Chromosome 16q has long been suspected of containing multiple tumor suppressor genes. DERPC in close proximity to multi-tumor tissue array. Despite small sample size, reduced tumor-specific expression was remarkable in renal tumor tissues compared with the normal counterpart. This finding provided a strong indication of the possible involvement of DERPC in renal tumors. Because of the limited size of samples, further study is necessary to establish the correlation of DERPC expression and renal tumors.
In prostate tumors, LCM-derived RNA samples were used to assess the expression changes of DERPC by quantitative RT-PCR. We found that the prostate tumors exhibited decreased expression of DERPC in E-cadherin warranted further evaluation. First, expression of DERPC was investigated in paired normal and tumor samples. DERPC expression was decreased in more than half of the renal tumors in We have demonstrated that DERPC has a diffuse nucleoplasmic localization by fusing GFP at the N-or C-termini of DERPC. Most transcription factors are classified as proteins with a diffuse nucleoplasmic distribution (36) . DERPC contains a proline-rich domain with abundant proline residues (20%), a feature found in many proteins that are involved in protein-protein interactions. DERPC also contains 11 repeats of the sequence PXXP. This motif has been shown to play a role in signal transduction by interacting with SH3 domain containing proteins (37, 38) . All high-affinity SH3 binding proteins contain this motif, and their binding specificity is conferred by the variable residues found within and flanking this consensus PXXP sequence. The presence of this motif in DERPC suggests that the protein might function as a binding protein of SH3 domain-containing proteins and could be involved in regulation or modification of these binding partners, many of which play important roles in the growth factor and signal transduction pathways (39, 40) . It is tempting to think that DERPC may interfere with growth factor or stress-mediated signal transduction pathways by interacting with SH3 domain containing molecules. Preliminary data showing cell growth inhibitory effects of DERPC suggests its potential role in negative regulation of cell growth and loss of such function could favor tumorigenesis. Further study will address the potential biochemical function of DERPC in signal transudation and cell growth. 5 cells) were plated in a 60 m culture dish for 24 hr and incubated at 37 ЊC. For transfection, 5g each of pcDNA3.1(ϩ), pcDNA-DERPC (sense), or pcDNA-DERPC(antisense) was transfected using TransFast reagent (Promega) according to the protocols provided. After 24 hr, cells were cultured in medium containing 400-500g/ml of geneticin (G-418) for 2-4 weeks. Cell colonies were stained with crystal violet (1 mg/ml).
